To clinically validate specific applications of company's MRI tools
Revolutions Medical (RevMed) has introduced its proprietary suite of MRI software products at Radiology Society of North America (RSNA). It plays an important role in the company’s ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch.
RevMed, CEO of Ron Wheet, said: “I could not be more pleased about the overwhelming interest that our MRI tools generated at this first introduction of our technology, and moreover at the premier imaging conference in the world.
“Introducing our proprietary MRI product offering at this conference was a dramatic step forward to commercialisation in 2010. Radiologists immediately understood the utility of our products. Universities, OEM and VAR providers requested follow-up discussions regarding clinical collaboration.
“They also want to explore delivery options, i.e. embedding our product content into their existing commercially available products. Timely hot topics at the show included MRI analysis in breast disease, and brain abnormalities such as the depth of injury in concussion (as reported by the NFL); these led to discussions as to how our unique MRI color software would aid in image analysis, thereby enhancing diagnostic confidence in an entirely different way.”
Tom O’Brien, president and participant in his 29th RSNA of RevMed, said: “Our CTO Rich Theriault and I spent several days meeting with a number of companies that ranged from MRI system providers to PACS/value-added resellers. We were excited to find that our MRI tools were both unique. Just as important, our business model of offering our products through a web-based SAS (software-as-service) is ahead of the curve.
“We are going to deliver our products via a web browser model right from the beginning, giving us a decided commercial advantage as vendors rush to add valuable content (like our proprietary MRI software tools) to their existing products. It is clear that this is the future direction of the medical imaging industry.”